CN1649575A - 用氨芬酸或奈帕芬胺治疗血管内皮生长因子介导的血管疾病的方法 - Google Patents

用氨芬酸或奈帕芬胺治疗血管内皮生长因子介导的血管疾病的方法 Download PDF

Info

Publication number
CN1649575A
CN1649575A CNA038094797A CN03809479A CN1649575A CN 1649575 A CN1649575 A CN 1649575A CN A038094797 A CNA038094797 A CN A038094797A CN 03809479 A CN03809479 A CN 03809479A CN 1649575 A CN1649575 A CN 1649575A
Authority
CN
China
Prior art keywords
disease
amfenac
nepafenac
edema
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038094797A
Other languages
English (en)
Chinese (zh)
Inventor
D·P·宾加曼
M·A·考平
D·A·格玛施
G·格拉夫
J·M·亚妮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1649575A publication Critical patent/CN1649575A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA038094797A 2002-05-03 2003-04-16 用氨芬酸或奈帕芬胺治疗血管内皮生长因子介导的血管疾病的方法 Pending CN1649575A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37742902P 2002-05-03 2002-05-03
US60/377,429 2002-05-03

Publications (1)

Publication Number Publication Date
CN1649575A true CN1649575A (zh) 2005-08-03

Family

ID=29401494

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038094797A Pending CN1649575A (zh) 2002-05-03 2003-04-16 用氨芬酸或奈帕芬胺治疗血管内皮生长因子介导的血管疾病的方法

Country Status (11)

Country Link
US (2) US20030207941A1 (enExample)
EP (1) EP1507522A2 (enExample)
JP (1) JP2005525408A (enExample)
KR (1) KR20040101499A (enExample)
CN (1) CN1649575A (enExample)
AU (1) AU2003231730A1 (enExample)
BR (1) BR0309747A (enExample)
CA (1) CA2483275A1 (enExample)
MX (1) MXPA04010132A (enExample)
PL (1) PL373787A1 (enExample)
WO (1) WO2003092669A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
WO2006056823A1 (en) * 2004-11-26 2006-06-01 Novagali Pharma Sa Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20080293691A1 (en) * 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
JP2012062258A (ja) * 2010-09-14 2012-03-29 Oriza Yuka Kk 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物
ES2686675T3 (es) * 2013-03-29 2018-10-19 Askat Inc. Agente terapéutico para enfermedad ocular
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
WO2001015744A1 (en) * 1999-08-31 2001-03-08 The Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
US6646003B2 (en) * 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac

Also Published As

Publication number Publication date
EP1507522A2 (en) 2005-02-23
JP2005525408A (ja) 2005-08-25
WO2003092669A2 (en) 2003-11-13
BR0309747A (pt) 2005-04-26
US20050143468A1 (en) 2005-06-30
AU2003231730A1 (en) 2003-11-17
PL373787A1 (en) 2005-09-19
KR20040101499A (ko) 2004-12-02
CA2483275A1 (en) 2003-11-13
US20030207941A1 (en) 2003-11-06
MXPA04010132A (es) 2005-01-25
WO2003092669A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
JP4970685B2 (ja) 眼痛の処置方法
AU2001238313A1 (en) Method for treating ocular pain
JP2011530496A (ja) 眼新生血管形成症状の治療のためのソラフェニブを含む眼科用医薬組成物
JP2012193214A (ja) ベンゾイルフェニル酢酸を使用して、血管形成関連障害を処置するための方法
CN1126072A (zh) 减低眼内压的眼用制剂
TW200305398A (en) Use of ROM production and release inhibitors to treat and prevent intraocular damage
WO2023202705A1 (zh) 一种眼用制剂及其在治疗老花眼中的应用
Chen et al. Nonsteroidal anti-inflammatory drugs for retinal neurodegenerative diseases
CN111683682A (zh) 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
EP0672417A1 (en) Reduction of elevated intraocular pressure
CN1649575A (zh) 用氨芬酸或奈帕芬胺治疗血管内皮生长因子介导的血管疾病的方法
CA2463282A1 (en) Therapeutical agent for pruritus
WO2025232814A1 (zh) 腺苷a2a受体拮抗剂在青光眼治疗及预防中的应用
US20230338307A1 (en) Prophylactic agent, ameliorating agent, and therapeutic agent for dry eye
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
TW200800261A (en) Compounds for the treatment of dryness of the ocular surface caused by photorefractive surgery
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤
TW201838629A (zh) 用於預防近視、治療近視及／或預防近視增長之包含蕪地銨作爲活性成分的藥劑
CN116270442B (zh) 一种用于矫正近距离视力的眼用制剂
JPWO2006098292A1 (ja) 眼疾患治療剤
US8207226B1 (en) Use of FAAH antagonists for treating dry eye and ocular pain
Baha'a et al. Effect of nadolol in treatment of induced ocular hypertension in rabbits
Nardi Nepafenac in the prevention and treatment of ocular inflammation and pain following cataract surgery in the prevention of post-operative macular oedema in diabetic patients
BRPI0710122A2 (pt) inibidores de preniltransferase para controle de hipertensão ocular e tratamento de glaucoma
WO2025140240A1 (zh) 一种用于治疗和/或预防角膜损伤的药物组合物和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication